COSCIENS Biopharma (NASDAQ:CSCI) Shares Down 15.3% – Here’s Why

COSCIENS Biopharma Inc. (NASDAQ:CSCI) was down 15.3% on Friday . The stock traded as low as $2.50 and last traded at $2.61. Approximately 58,328 shares traded hands during mid-day trading, an increase of 186% from the average daily volume of 20,392 shares. The stock had previously closed at $3.08.

COSCIENS Biopharma Stock Down 15.3%

The firm has a fifty day moving average of $3.46 and a 200-day moving average of $3.30. The stock has a market capitalization of $8.29 million, a price-to-earnings ratio of -0.43 and a beta of 0.91.

COSCIENS Biopharma (NASDAQ:CSCI) last posted its earnings results on Thursday, August 14th. The company reported ($0.85) earnings per share for the quarter. The firm had revenue of $2.75 million during the quarter. COSCIENS Biopharma had a negative net margin of 199.55% and a negative return on equity of 149.49%.

COSCIENS Biopharma Company Profile

COSCIENS Biopharma Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.